APA (7th ed.) Citation

Antonioli, E., Staderini, M., Pilerci, S., Perfetto, F., Cappelli, F., Allinovi, M., . . . Bosi, A. (2020). Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: A real-life single-center experience. Leukemia & Lymphoma, 61(13), 3255. https://doi.org/10.1080/10428194.2020.1802452

Chicago Style (17th ed.) Citation

Antonioli, Elisabetta, et al. "Daratumumab, Lenalidomide, and Dexamethasone Combination in Relapsed/refractory Myeloma Patients: A Real-life Single-center Experience." Leukemia & Lymphoma 61, no. 13 (2020): 3255. https://doi.org/10.1080/10428194.2020.1802452.

MLA (9th ed.) Citation

Antonioli, Elisabetta, et al. "Daratumumab, Lenalidomide, and Dexamethasone Combination in Relapsed/refractory Myeloma Patients: A Real-life Single-center Experience." Leukemia & Lymphoma, vol. 61, no. 13, 2020, p. 3255, https://doi.org/10.1080/10428194.2020.1802452.